Skip to Content

Laronidase Side Effects

For the Consumer

Applies to laronidase: intravenous solution

In addition to its needed effects, some unwanted effects may be caused by laronidase. In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking laronidase, check with your doctor or nurse immediately:

More common:
  • Abdominal or stomach pain
  • accumulation of pus
  • back pain
  • black, tarry stools
  • bleeding gums
  • blood in urine or stools
  • blurred vision
  • chest pain
  • chest tightness
  • chills
  • clay-colored stools
  • confusion
  • dark urine
  • dizziness
  • drowsiness
  • facial swelling
  • faintness
  • fast, pounding, or irregular heartbeat or pulse
  • fever
  • flushing
  • headache
  • hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at injection site
  • itching
  • lightheadedness when getting up from a lying or sitting position suddenly
  • loss of appetite
  • nausea or vomiting
  • pale skin
  • pinpoint red spots on skin
  • shortness of breath
  • skin rash
  • sweating
  • swollen, red, or tender area of infection
  • trouble breathing
  • unpleasant breath odor
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting of blood
  • yellow eyes or skin
Less common:
  • Cough
  • difficulty breathing
  • itching skin
  • large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • noisy breathing
  • redness of skin
  • tightness in chest
  • wheezing

Minor Side Effects

Some of the side effects that can occur with laronidase may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Bleeding, blistering, burning, coldness, or discoloration of skin
  • blindness
  • body aches or pain
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • decreased vision
  • diarrhea
  • difficulty in moving
  • ear congestion
  • feeling of pressure
  • loss of voice
  • muscle pain or stiffness
  • nasal congestion
  • overactive reflexes
  • pain in joints
  • runny nose
  • sneezing
  • sore throat
  • swelling of legs and feet
  • swelling or puffiness of face
  • varicose or spider veins

For Healthcare Professionals

Applies to laronidase: intravenous solution


The most frequently reported infusion reactions included pyrexia, chills, blood pressure, increased, tachycardia, and oxygen saturation decreased.

The most frequently reported adverse reactions included rash, upper respiratory tract infection, injection site reaction, hyperreflexia, paresthesia, flushing, and poor venous access.[Ref]


Common (1% to 10%): Anaphylactic reaction[Ref]


Very common (10% or more): Infusion reactions (up to 49%), pyrexia (up to 30%), otitis media (20%), chills (up to 20%), central venous catheterization required for infusion (15%), oxygen saturation decreased (up to 10%)
Common (1% to 10%): Chest pain, face edema, gravitational/dependent edema, abscess, feeling hot, feeling cold, influenza-like illness, body temperature increased
Frequency not reported: Laryngeal edema, extravasation
Postmarketing reports: Fatigue[Ref]

The most common adverse reactions were infusion reactions; the frequency decreased over time with continued use, and most were classified as mild to moderate in severity. The majority of infusion reactions requiring intervention were ameliorated with slowing of the infusion rate, temporarily stopping the infusion, with or without administering additional antihistamines and/or antipyretics.[Ref]


Very common (10% or more): Nausea, abdominal pain/discomfort
Common (1% to 10%): Vomiting, diarrhea[Ref]


In clinical trials, 99 of 102 patients developed IgG antidrug antibodies. No correlation was demonstrated between presence of antidrug antibodies and therapeutic response or the occurrence of allergic reactions. There was also no consistent association between presence of antibodies that neutralize enzymatic activity and therapeutic response. The potential for antibody neutralization of cellular uptake has not been evaluated. There were 9 patients collectively in clinical studies who experienced severe infusion reactions and were subsequently tested for drug specific IgE antibodies and complement activation. Following testing, 1 of the 9 patients had an anaphylactic reaction consisting of urticaria and airway obstruction and tested positive for both drug specific IgE binding antibodies and complement activation. In a separate open-label study of patients 5 years and younger, none tested positive for IgE. The clinical significance of IgE antibodies has not been established.[Ref]

Very common (10% or more): Antidrug antibody development (97%)
Postmarketing reports: Anaphylactic shock, IgE antibody development, compliment activation[Ref]


Very common (10% or more): Rash (up to 36%)
Common (1% to 10%): Angioedema, urticaria, pruritus, hyperhidrosis, alopecia, cold sweat
Frequency not reported: Erythema[Ref]


Very common (10% or more): Injection site reaction (up to 18%)
Common (1% to 10%): Injection site pain[Ref]


Very common (10% or more): Upper respiratory tract infection (32%)
Common (1% to 10%): Respiratory distress, dyspnea, cough, wheezing, pulmonary crepitation
Frequency not reported: Bronchospasm, hypoxia, tachypnea, respiratory arrest
Postmarketing reports: Respiratory failure, pneumonia[Ref]


Very common (10% or more): Flushing (up to 23%), poor venous access/vein disorder (14%), blood pressure increased (up to 10%), tachycardia (up to 10%)
Common (1% to 10%): Hypotension, pallor, peripheral coldness
Frequency not reported: Cyanosis
Postmarketing reports: Cardiorespiratory arrest, cardiac failure[Ref]

Nervous system

Very common (10% or more): Hyperreflexia (14%), paresthesia (14%), headache
Common (1% to 10%): Dizziness, tremor[Ref]


Common (1% to 10%): Thrombocytopenia[Ref]


Common (1% to 10%): Hyperbilirubinemia, bilirubinemia[Ref]


Common (1% to 10%): Corneal opacity[Ref]


Very common (10% or more): Arthropathy, arthralgia, back pain, pain in extremity
Common (1% to 10%): Musculoskeletal pain[Ref]


Common (1% to 10%): Restlessness[Ref]


1. "Product Information. Aldurazyme (laronidase)." Genzyme Corporation, Cambridge, MA.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Not all side effects for laronidase may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.